Anticipated shortage
Anticipated shortage as biosimilar transition creates temporary supply gap. AbbVie winding down branded product supply.
Expected resolution: 31 October 2025
Alternatives:
- Hadlima — adalimumab biosimilar
- Amgevita — adalimumab biosimilar
- Idacio — adalimumab biosimilar
adalimumab
Humira
40 mg/0.8 mL · injection · Biologics
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $1,248.00 |
PBS Information
- Item code
- IMM010
- Drug name
- adalimumab
- Brand name
- Humira
- Manufacturer
- AbbVie
- Formulation
- injection
- Strength
- 40 mg/0.8 mL
- Max quantity
- 2 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- Biologics
TGA Reference: TGA-MSI-2025-018 · Sponsor: AbbVie Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.